• linkedin
  • Increase Font
  • Sharebar

    Alzheimer’s vaccine targets early and later disease stages

    Researchers in the United States and Australia are working together to develop a vaccine that they believe could have both preventive and therapeutic effects on Alzheimer’s disease.

    The vaccine, detailed in a study titled, “Alzheimer’s disease AdvaxCpG- adjuvanted MultiTEP-based dual and single vaccines induce high-titer antibodies against various forms of tau and Aβ pathological molecules,” and published in Nature’s Scientific Reports journal, targets two types of proteins involved in early and late pathogenesis of Alzheimer’s disease.

    Alzheimer’s disease is an irreversible, progressive brain disease affecting nearly 46 million people across the globe. Often manifesting after age 60, the disease inhibits memory and cognitive skills, making even simple tasks difficult, according to the National Institute on Aging (NIA).

    Researchers at Flinders University in Australia, the University of California-Irvine and the Institute of Molecular Medicine—a California non-profit aimed at fighting chronic diseases—are studying a vaccine to fight Alzheimer’s disease by inducing antibodies against both aggregated β-amyloid (Aβ) and Tau proteins, helping to remove them from the brain and restore normal brain function, said Nikolai Petrovsky, PhD, director of endocrinology at Flinders Medical Centre and professor of medicine at Flinders University.

    “It is different from previous vaccines in that it is between 100 and 1,000 times more potent at antibody induction than previous versions,” Petrovsky told Medical Economics. “This is critical to vaccine success as we now know that very high levels of antibodies are required for protection and this likely explains the failures of previous generations of vaccines.”

    Next: Vaccine for early intervention

    Rachael Zimlich, RN
    Ms Zimlich is a freelance writer in Cleveland, Ohio. She writes regularly for Contemporary Pediatrics, Managed Healthcare Executive, and ...


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Latest Tweets Follow